NervGen Pharma Acquired | Healthcare M&A Deal

NervGen Pharma acquisition: NervGen Pharma Corp. has completed the acquisition of NervGen Pharma, a pharmaceuticals business in Vancouver, British Columbia, for $60.0 million. NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, supporting healthcare M&A in pharmaceuticals. The company’s NVG-291 program is designed to advance through clinical studies, aligning with pharmaceuticals acquisition objectives in healthcare M&A. This other acquisition is structured as an underwritten public offering of 24,000,000 common shares with accompanying warrants, priced at $2.50 per share and a $3.68 exercise price, expected to close May 26, 2026, with joint bookrunning managers Leerink Partners and TD Cowen.